Navigation Links
Infinity and MedImmune to Present Preclinical Data From Study of,Oral Formulation of IPI-504 At AACR

Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR

CAMBRIDGE, Mass. and GAITHERSBURG, Md., April 10, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that data from a preclinical study with an oral formulation of IPI-504 in non-small cell lung cancer (NSCLC) will be presented at the upcoming Annual Meeting of the American Association for Cancer Research (AACR) in Los Angeles, Calif., April 14-18, 2007. IPI-504, the companies' heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated as a water-soluble, intravenous formulation in two disease-focused clinical trials involving patients with gastrointestinal stromal tumors (GIST) and NSCLC.

An oral presentation of the data, titled "IPI-504, a novel orally administered Hsp90 inhibitor, demonstrates anti-tumor effects in EGFR mutant, kinase inhibitor resistant NSCLC" (Abstract No. 5726) is scheduled to begin at 9:10 a.m. PDT on Wednesday, April 18, 2007 in Room 501 A-C in the Los Angeles Convention Center.

About IPI-504

IPI-504 is a small molecule drug candidate being developed jointly by Infinity and MedImmune. IPI-504 has been well-tolerated in its ongoing Phase I studies and has shown promising biological activity in a Phase I clinical trial in patients with relapsed, refractory Gleevec(r)-resistant GIST. IPI-504 is also being evaluated in a Phase I/II clinical trial in patients with advanced NSCLC. In preclinical studies, IPI-504 has been shown to inhibit Hsp90 potently and selectively, thereby killing cancer cells. IPI-504 has also demonstrated, in preclinical studies, broad potential to treat certain cancers as both a single agent as well as in combination with existing anti-cancer drugs. The water-based formulation of IPI-504 is delivered as an intravenous infusion; an oral formulation of IPI-504 is currently
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. The Past, Present and Future of HLA Typing
11. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/6/2008)...land, October 7 /-,Sosei Gr... and Vectura,Group plc ("Vectura"; LSE: VEC), anno...e efficacy, safety and tolerability of NVA237 pres...ratory Society (ERS) in Berlin,Germany. The new d...ovel,inhaled long-acting muscarinic antagonist (LA...
(Date:10/6/2008)...e-USNewswire/ -- "A return to the use of,chimpanze...hout scientific,justification," according to a pap...aboratory Animals (ATLA). "An Assessment of the Ro...des that vaccine responses in,chimpanzees are not ... of,chimpanzees, critical role and importance in A...
(Date:10/6/2008)...eature children, parents discussing clinical ... Oct. 6 /PRNewswire-USNewswire/ -- From asthma and...en saves lives and improves their,health and well-... of,Health (NIH), "Children and Clinical Studies",...gov ), offers parents and health,care providers an...
(Date:10/6/2008)...udies with Durezol Dosed Prior to Surgery, TAMPA,... Inc., a,privately held ophthalmic-focused biophar...M) (difluprednate ophthalmic emulsion) 0.05% is no...ved by the U.S. Food and,Drug Administration in Ju...dicated for the treatment of inflammation and pain...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Insects use plant like a telephone 3011 1LifeSync Corporation Agrees to Sublicense Patent Portfolio to Triage Wireless 17527 1WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008 17524 1WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008 17524 2WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008 17524 3WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008 17524 4WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008 17524 5WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008 17524 6WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008 17524 7WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008 17524 8WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008 17524 9Increase in Travel to China Creating New Health and Security Risks 17521 1Increase in Travel to China Creating New Health and Security Risks 17521 2
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...n vegetables like spinach and lettuce, may be resp...new study//. Past studies have shown that a diet ...ssure. But it has been difficult to determine ex...uits and vegetables are responsible for these bloo...
...ng sessions can prompt women to both scale back ri...tion, according to a new study//. Prenatal alcohol...defects and developmental disabilities in the Unit...trategy that could reduce a woman’s risk of an alc...
... has brought to light that taking drugs to ease h...e// the chances of landing with a fractured hip so...sec are drugs used to relieve heartburn.The risk ...rs of age. The researchers have postulated that th...
...ces of dioxin in a U.S. beef consignment to Seoul,...he U.S. officials and the American beef industry a...ally high levels of dioxin, at 6.26 picograms, whi...5-picogram level. USDA spokesman Keith Williams s...
Other Medicine News:Health News:Counseling Helps Young Women Cut Drinking, Improve Contraception Use 2Health News:Counseling Helps Young Women Cut Drinking, Improve Contraception Use 3Health News:Taking Drugs for Heartburn may Cause Fractured Hip 2
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Rhoton #12 straight point needle semisharp, titanium.
Rhoton scissors curved tip.
Medicine Products: